68Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy.
AIM
The aim of this study was to develop a dual-modality positron emission tomography/magnetic resonance (PET/MR) imaging probe by radiolabeling gadolinium-containing AGuIX derivatives with the positron-emitter Gallium-68 (68Ga).


MATERIALS & METHODS
AGuIX@NODAGA nanoparticles were labeled with 68Ga at high efficiency. Tumor accumulation in an appropriate disease model was assessed by ex vivo biodistribution and in vivo PET/MR imaging.


RESULTS
68Ga-AGuIX@NODAGA was proven to passively accumulate in U87MG human glioblastoma tumor xenografts. Metabolite assessment in serum, urine and tumor samples showed that 68Ga-AGuIX@NODAGA remains unmetabolized up to at least 60 min postinjection.


CONCLUSION
This study demonstrates that 68Ga-AGuIX@NODAGA can be used as a dual-modality PET/MR imaging agent with passive accumulation in the diseased area, thus showing great potential for PET/MR image-guided radiation therapy.
['Bouziotis|Penelope|P|', 'Stellas|Dimitris|D|', 'Thomas|Eloïse|E|', 'Truillet|Charles|C|', 'Tsoukalas|Charalampos|C|', 'Lux|François|F|', 'Tsotakos|Theodoros|T|', 'Xanthopoulos|Stavros|S|', 'Paravatou-Petsotas|Maria|M|', 'Gaitanis|Anastasios|A|', 'Moulopoulos|Lia Angela|LA|', 'Koutoulidis|Vassilis|V|', 'Anagnostopoulos|Constantinos D|CD|', 'Tillement|Olivier|O|']
D000085:Acetates D000818:Animals D045744:Cell Line, Tumor D016543:Central Nervous System Neoplasms D002851:Chromatography, High Pressure Liquid D003287:Contrast Media D056831:Coordination Complexes D005260:Female D005710:Gallium Radioisotopes D005909:Glioblastoma D006573:Heterocyclic Compounds, 1-Ring D006801:Humans D008279:Magnetic Resonance Imaging D051379:Mice D016513:Mice, SCID D053758:Nanoparticles D049268:Positron-Emission Tomography D012833:Siloxanes D014018:Tissue Distribution
Gallium-68 PET/MR imaging ultrasmall AGuIX nanoparticles